Julie Little

Julie is Associate Director of our Strategic Alliances team, the team who manage long-term, strategic alliances with one or more external partners to translate novel research based on shared values and common goals to address a cancer challenge. They support building of new alliances and are also responsible for business intelligence, data analysis and post-deal administration.

Julie joined Cancer Research Horizons in 2012. She played key roles in establishing alliances with Merck Healthcare KGaA, AstraZeneca, and Abcam. She now leads the Strategic Alliance Team responsible for a portfolio of alliances in Europe, US and Japan focused on translating exciting discoveries to improve patient outcomes.

Julie obtained her degree in Biological Sciences from Exeter University. Her MSc in Molecular Biology and Biotechnology, University College London, involved a placement at Unilever plc leading to a career there of over 16 years where she gained her MPhil and worked on discovery research projects including antibodies for personal care products. Julie moved to Genzyme Therapeutics Ltd to help establish a new Cambridge research facility. She led the phage display team developing therapeutic antibodies for a range of indications and developed anti-idiotype antibodies to support clinical development of the now approved multiple sclerosis drug, Lemtrada.